Key Takeaways
- UCB has agreed to acquire Neurona Therapeutics for over $1 billion, enhancing its epilepsy portfolio.
- The deal includes $650 million in cash and up to $500 million in future milestone payments.
- NRTX-1001, Neurona’s cell therapy, aims to treat drug-resistant mesial temporal lobe epilepsy.
UCB Expands Epilepsy Portfolio with Neurona Acquisition
Belgium’s UCB is making headlines in the pharmaceutical industry with its recent acquisition of cell therapy biotech Neurona Therapeutics, a deal potentially valued at over $1 billion. As part of its strategic commitment to inorganic growth, UCB aims to enhance its longstanding focus on epilepsy treatment.
The agreement marks UCB’s investment of $650 million in cash and includes the possibility of up to $500 million in future milestone payments. The acquisition is expected to be finalized by the end of this quarter.
Neurona Therapeutics is known for its lead candidate, NRTX-1001, a neuronal cell therapy currently undergoing phase I/II clinical trials. This therapy is designed for patients suffering from drug-resistant mesial temporal lobe epilepsy (mTLE). As a pluripotent stem cell treatment, NRTX-1001 is administered as a single dose directly into the brain, with the goal of introducing cells that produce gamma-aminobutyric acid (GABA). This mechanism aims to “repair and rebalance the overactive neural networks” associated with mTLE, potentially reducing the frequency of seizures.
UCB’s Chief Executive, Jean-Christophe Tellier, expressed optimism regarding NRTX-1001, stating that it has the potential to provide sustained repair of the nervous system after just one dose, representing a significant advancement for individuals with mTLE.
The acquisition of Neurona follows UCB’s prior agreement in 2022 to purchase Zogenix, another epilepsy-focused company, for up to $1.9 billion, which brought the promising drug Fintepla into UCB’s portfolio. That drug generated €427 million in sales last year and is on track for a potential label expansion into a third type of epilepsy following successful trial results.
The biopharmaceutical sector has experienced a notable surge in mergers and acquisitions, with approximately $30 billion in transactions reported in the latter half of March alone. This trend has continued into April, featuring additional acquisitions from companies like Neurocrine and Eli Lilly. UCB’s strategic move not only secures a vital new therapy but also solidifies its position within the competitive landscape of advanced medicine and treatment for neurological disorders.
The content above is a summary. For more details, see the source article.